Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 7 results
Filters: First Letter Of Title is R and Author is Bosch, Ronald J  [Clear All Filters]
Found 7 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

R

J Kilby M, R Bucy P, Mildvan D, et al. "A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024)." J. Infect. Dis.. 2006;194(12):1672-6.
Gandhi RT, O'Neill D, Bosch RJ, et al. "A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy." Vaccine. 2009;27(43):6088-94.
Bosch RJ, Pollard RB, Landay A, Aga E, Fox L, Mitsuyasu R. "A randomized trial of interleukin-2 during withdrawal of antiretroviral treatment." J. Interferon Cytokine Res.. 2011;31(6):481-3.
Smurzynski M, Wu K, Benson CA, Bosch RJ, Collier AC, Koletar SL. "Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study." J. Acquir. Immune Defic. Syndr.. 2010;55(1):117-27.
Gandhi RT, Bosch RJ, Aga E, et al. "Residual plasma viraemia and infectious HIV-1 recovery from resting memory CD4 cells in patients on antiretroviral therapy: results from ACTG A5173." Antivir. Ther. (Lond.). 2013;18(4):607-13.
Clark SA, Shulman NS, Bosch RJ, Mellors JW. "Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors." AIDS. 2006;20(7):981-4.
Tenorio AR, Chan ES, Bosch RJ, et al. "Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286." J. Infect. Dis.. 2015;211(5):780-90.